Difference between revisions of "Prescribing - Donkey"
(2 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
==Prescribing for donkeys== | ==Prescribing for donkeys== | ||
− | + | [[Image:Donkey Mexico.JPG|thumb|right|200px|<small><center>Image courtesy of [http://drupal.thedonkeysanctuary.org.uk The Donkey Sanctuary]</center></small>]] | |
Pharmacokinetic differences have been demonstrated between horses and donkeys for a number of drugs e.g. oxytetracycline (Horspool ''et al'', 1990), trimethoprim-sulfamethoxazole (Peck ''et al'', 2002), phenylbutazone (Mealey ''et al'', 1997, Matthews ''et al'', 2001), flunixin meglumine (Coakley ''et al'', 1999), and guaifenesin (Matthews ''et al'', 1997) with, in general, Vd being lower, CL being higher and/or t½ being shorter in donkeys than in horses. These differences are of potential clinical significance for some, but not all, drugs that undergo hepatic biotransformation (Peck ''et al'', 1997). The NSAID carprofen is apparently metabolised more slowly in donkeys than in horses (Mealey 'et al'', 2004). | Pharmacokinetic differences have been demonstrated between horses and donkeys for a number of drugs e.g. oxytetracycline (Horspool ''et al'', 1990), trimethoprim-sulfamethoxazole (Peck ''et al'', 2002), phenylbutazone (Mealey ''et al'', 1997, Matthews ''et al'', 2001), flunixin meglumine (Coakley ''et al'', 1999), and guaifenesin (Matthews ''et al'', 1997) with, in general, Vd being lower, CL being higher and/or t½ being shorter in donkeys than in horses. These differences are of potential clinical significance for some, but not all, drugs that undergo hepatic biotransformation (Peck ''et al'', 1997). The NSAID carprofen is apparently metabolised more slowly in donkeys than in horses (Mealey 'et al'', 2004). | ||
Line 22: | Line 22: | ||
product approved for use in the horse should be selected and used at the | product approved for use in the horse should be selected and used at the | ||
approved dose rate and regime. | approved dose rate and regime. | ||
+ | |||
+ | ==Literature Search== | ||
+ | [[File:CABI logo.jpg|left|90px]] | ||
+ | |||
+ | |||
+ | Use these links to find recent scientific publications via CAB Abstracts (log in required unless accessing from a subscribing organisation). | ||
+ | <br><br><br> | ||
+ | [http://www.cabdirect.org/search.html?q=(donkey+horse)+AND+subject:(pharmacology) Pharmacology and donkeys and horses publications] | ||
==References== | ==References== | ||
Line 50: | Line 58: | ||
|Maintitlebackcolour = B4CDCD | |Maintitlebackcolour = B4CDCD | ||
}} | }} | ||
+ | [[Category:Pharmacology_-_Donkey]] |
Latest revision as of 11:23, 23 October 2010
This article has been peer reviewed but is awaiting expert review. If you would like to help with this, please see more information about expert reviewing. |
Prescribing for donkeys
Pharmacokinetic differences have been demonstrated between horses and donkeys for a number of drugs e.g. oxytetracycline (Horspool et al, 1990), trimethoprim-sulfamethoxazole (Peck et al, 2002), phenylbutazone (Mealey et al, 1997, Matthews et al, 2001), flunixin meglumine (Coakley et al, 1999), and guaifenesin (Matthews et al, 1997) with, in general, Vd being lower, CL being higher and/or t½ being shorter in donkeys than in horses. These differences are of potential clinical significance for some, but not all, drugs that undergo hepatic biotransformation (Peck et al, 1997). The NSAID carprofen is apparently metabolised more slowly in donkeys than in horses (Mealey 'et al, 2004).
Dose rates and/or dosing regimens should not be altered unless there is sufficient evidence, based on controlled studies or best practice guidelines, for a particular drug. The dose rates cited in this chapter are based either on published literature or on the recommendations made by The Donkey Sanctuary (Trawford, 2004).
Most commonly, there is no approved product for use in the donkey. In the EU, equines are considered food-producing animals with the consequent implications in terms of what drugs can be administered and withdrawal periods. Donkeys are frequently kept as companion or leisure animals and are not usually intended for human consumption. Legislation has been put in place in the EU that covers equines of this type (Trawford, 2004). The range of medicines that can be used in the latter group can then be based on the so-called prescribing cascade (Bishop, 2001). In the absence of a veterinary product with market authorisation for use in donkeys, a veterinary product approved for use in the horse should be selected and used at the approved dose rate and regime.
Literature Search
Use these links to find recent scientific publications via CAB Abstracts (log in required unless accessing from a subscribing organisation).
Pharmacology and donkeys and horses publications
References
- Horspool, L. (2008) Clinical pharmacology In Svendsen, E.D., Duncan, J. and Hadrill, D. (2008) The Professional Handbook of the Donkey, 4th edition, Whittet Books, Chapter 12
- Bishop, Y. (2000). ‘Code of Practice on Medicines’. Veterinary Formulary. 5th edition. Y. Bishop (ed). The Pharmaceutical Press, London. pp 5-8.
- Coakley, M., Peck, K.E., Taylor, T.S., Matthews, N.S., and Mealey, K.L. (1999). ‘Pharmacokinetics of flunixin meglumine in donkeys, mules and horses’. American Journal of Veterinary Research 60. pp 1441-1444.
- Horspool, L.J.I., McKellar, Q.A. (1990). ‘Disposition of oxytetracycline in horses, ponies and donkeys after intravenous administration’. Equine Veterinary Journal 22(4). pp 284-285.
- Matthews, N.S., Peck, K.E., Mealey, K.L., Taylor, T.S., and Ray, A.C. (1997). ‘Pharmacokinetics and cardiopulmonary effects of guaifenesin in donkeys’. Journal of Veterinary Pharmacology and Therapeutics 20. pp 442-226.
- Matthews, N.S., Peck, K.E., Taylor, T.S., and Mealey, K.L. (2001). ‘Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys’. American Journal of Veterinry Research 62. pp 673-675.
- Mealey, K.L., Matthews, N.S., Peck, K.E., Burchfield, M.I., Bennett, B.S. and Taylor, T.S. (2004). ‘Pharmacokinetics of R(-) and S(+) carprofen after administration of racemic carprofen in donkeys and horses’. American Journal of Veterinary Research 65. pp 1479-1482.
- Mealey, K.L., Matthews, N.S., Peck, K.E., Ray, A.C., and Taylor, T.S. (1997). ‘Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys’. American Journal of Veterinary Research 58. pp 53-55.
- Peck, K., Mealey, K.L., Matthews, N.S., and Taylor, T.S. (1997). ‘Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys’. American Journal of Veterinary Research 58. pp 881-884.
- Peck, K.E., Matthews, N.S., Taylor, T.S., and Mealey, K.L. (2002). ‘Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses’. American Journal of Veterinary Research 63. pp 349-353.
- Trawford, A.F. (2004). ‘Prescribing for donkeys’. The Veterinary Formulary. 6th edition. Y. Bishop (ed). The Pharmaceutical Press, London.
|
This page was sponsored and content provided by THE DONKEY SANCTUARY |
---|